INM Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.39%

Insider Buying (Last 12 Months): $29,601.00

Insider Selling (Last 12 Months): $0.00

InMed Pharmaceuticals Insider Trading History Chart

InMed Pharmaceuticals Share Price & Price History

^$0.25

▼ -0.05 (-16.50%)

As of 04/25/2024 01:00 AM ET

Days: 30 | 90 | 365

World’s biggest multibillionaire investor is buying THIS by the ton [picture]

From Stansberry Research | Ad

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Click here to find out what to do.

InMed Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/21/2024	Andrew Hull	Director	Buy	37,500	$0.39	$14,625.00	38,258
2/20/2024	Eric A. Adams	CEO	Buy	41,600	$0.36	$14,976.00	43,959
4/13/2022	Eric A. Adams	CEO	Buy	8,560	$0.85	$7,276.00	44,843
1/24/2022	Bruce S. Colwill	CFO	Buy	5,000	$1.09	$5,450.00
1/6/2022	Shane Aaron Johnson	SVP	Buy	8,500	$1.26	$10,710.00
12/30/2021	Shane Aaron Johnson	SVP	Buy	8,093	$1.33	$10,763.69
11/15/2021	Shane Aaron Johnson	SVP	Buy	5,000	$1.37	$6,850.00
9/28/2021	Bruce S. Colwill	CFO	Buy	5,000	$1.77	$8,850.00
9/28/2021	Eric A. Adams	CEO	Buy	11,400	$1.75	$19,950.00

World’s biggest multibillionaire investor is buying THIS by the ton [picture]

From Stansberry Research | Ad

Click here to find out what to do.

SEC Filings (Institutional Ownership Changes) for InMed Pharmaceuticals (NASDAQ:INM)

20.12% of InMed Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

InMed Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/13/2024	Armistice Capital LLC	205,968	$86K	0.0%	N/A	3.916%
11/14/2022	Armistice Capital LLC	90,000	$0.59M	0.0%	-90.6%	9.605%
5/17/2022	Empery Asset Management LP	61,741	$58K	0.3%	N/A	0.437%
8/17/2021	Armistice Capital LLC	890,000	$2.83M	0.1%	+278.7%	9.954%
8/12/2021	Penserra Capital Management LLC	19,912	$49K	0.0%	N/A	0.223%
5/21/2021	Citadel Advisors LLC	17,211	$57K	0.0%	N/A	0.214%
5/18/2021	Citadel Advisors LLC	17,211	$57K	0.0%	N/A	0.214%
5/17/2021	Armistice Capital LLC	235,000	$0.78M	0.0%	N/A	2.919%
1/29/2021	Creative Planning	10,990	$36K	0.0%	N/A	0.157%

Data available starting January 2016

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Today's Range

Now: $0.25

$0.25

$0.27

50 Day Range

MA: $0.35

$0.25

$0.44

52 Week Range

Now: $0.25

$0.25

$2.08

Volume

619,988 shs

Average Volume

314,442 shs

Market Capitalization

$1.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.1

Who are the company insiders with the largest holdings of InMed Pharmaceuticals?: InMed Pharmaceuticals' top insider investors include:
Eric A Adams (CEO)
Andrew Hull (Director)
Learn More about top insider investors at InMed Pharmaceuticals.